Bausch Health rises 25% on bad earnings – is this pump a trap for retail investors?

Bausch Health’s (NASDAQ: BHC) pre-market rally is causing the ears of investors to prick up as the word gets out. While the sentiment appears to be positive at the moment investors could be in for a rollercoaster at the bell. Considering the pre-market is a usually a façade for the trading day, many investors are skeptical as to whether the rally will hold up.… Read more

Here’s how much a $10,000 investment in this COVID-19 vaccine company is worth now

The COVID-19 vaccine industry has seen immense investor backing with popular US listed companies such as Moderna, Pfizer and Vaxart multiplying their pre-COVID value upwards of 500%-1,000%. However, Novavax, Inc. (NASDAQ: NVAX) has surpassed it’s rivals in stock value growth, currently priced at $143.10. An investment of $10,000 in NVAX after the initial COVID-19 vaccine announcement in March, would now be worth over $207,000.… Read more

Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know

Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell therapies.… Read more

Vaxart rises 300% after its COVID-19 vaccine joins Trump’s Operation Warp Speed – is now the time to invest?

Vaxart Incorporated (NASDAQ: VXRT), wrenched the spotlight off COVID-19 frontrunners after its oral vaccine received funding from “Operation Warp Speed,” Trump’s accelerated vaccine program. The funding is causing investors to empty their wallets into the stock. The stock did skyrocket to the moon initially. However, now VXRT is following a downward spiral.… Read more

INO’s COVID-19 vaccine receives $71 million in government funding – how high can the INO stock go?

The COVID-19 vaccine market was fading as economies began to recover. However, the insurgence of new coronavirus cases and deaths is causing investors to gravitate towards COVID-19 vaccine frontrunners Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Inovio Pharmaceuticals (NASDAQ: INO). It makes logical sense that investors rally behind the vaccine companies.… Read more